EUVIMEDEUVIMED entdecken
Multizentrische Studie

HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome

Michele Bottosso, Renata L Sandoval, Benjamin Verret, Natalia Polidorio, Olivier Caron, Alessandra Gennari, Brittany L Bychkovsky, Sophie H Cahill, Maria I Achatz, Valentina Guarneri, Fabrice André, Judy E Garber

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114307 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Michele Bottosso und 11 weiteren Autor:innen. Beteiligte Einrichtung: INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France; Department of Surgery, Oncology and Gastroenterology, University of Padua, Italy. …. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy, Li-Fraumeni Syndrome, Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyLi-Fraumeni SyndromeBreast NeoplasmsHumansFemaleAdultMiddle AgedRetrospective StudiesYoung AdultAgedGerm-Line MutationTrastuzumabTumor Suppressor Protein p53

Stichwörter der Autor:innen

Breast cancerHER2HER2-lowLi-Fraumeni syndromeNeoadjuvant treatment

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabTumor Suppressor Protein p53ERBB2 protein, humanTP53 protein, human

Autor:innen und Institutionen

  • INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France; Department of Surgery, Oncology and Gastroenterology, University of Padua, Italy. Electronic address: michele.bottosso@iov.veneto.it.
  • Medical Oncology Center, Hospital Sírio-Libanês, Brasília, DF, Brazil.
  • INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France.
  • Breast Surgery Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gustave Roussy, Département de médecine oncologique, F-94805 Villejuif, France.
  • Department of Translational Medicine, University of Piemonte Orientale (UPO), Novara, Italy; Medical Oncology, "Maggiore Della Carità" University Hospital, Novara, Italy.

Zitieren

APA

Bottosso, M., Sandoval, R. L., Verret, B., Polidorio, N., Caron, O., Gennari, A., Bychkovsky, B. L., Cahill, S. H., Achatz, M. I., Guarneri, V., André, F., & Garber, J. E. (2024). HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114307

Vancouver

Bottosso M, Sandoval RL, Verret B, Polidorio N, Caron O, Gennari A, et al. HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114307

BibTeX
@article{Bottosso2024,
  author = {Bottosso, Michele and Sandoval, Renata L and Verret, Benjamin and Polidorio, Natalia and Caron, Olivier and Gennari, Alessandra and Bychkovsky, Brittany L and Cahill, Sophie H and Achatz, Maria I and Guarneri, Valentina and André, Fabrice and Garber, Judy E},
  title = {HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114307}
}
Kostenlos starten →